Owlet Inc Dossier - Source-backed chat

Owlet Inc

OWLTNYSE

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)1.59

Intrinsic Value $7.11median of 2 methodsbased on filings through 30 Jun 2026

Market Price $5.03Price as of 1 Oct 2026

UndervaluedIntrinsic value is 41% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $147M

Enterprise Value $133.1M

Shares Outstanding 30.6M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Owlet, Inc. is successfully transitioning from a pure-play hardware baby monitor company into a high-margin, data-driven pediatric health platform. Under the leadership of returning co-founder and CEO Kurt Workman, the company is prioritizing high-margin subscription revenue (Owlet360) and expanding its ecosystem with the launch of the OnCall Telehealth platform. Despite macroeconomic headwinds and tariff pressures, Owlet's strong market share expansion, improving gross margins, and significantly upgraded FY 2026 Adjusted EBITDA guidance make it a compelling growth story in the pediatric wellness space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$13.00

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Escalating tariff costs exceed the anticipated 15% baseline, severely compressing gross margins. Declining birth rates in core markets (US and UK) act as a structural headwind, and subscriber growth for Owlet360 plateaus, causing the company to miss its revised FY 2026 revenue guidance of $118 million to $122 million.

Base CaseCentral scenario

The company successfully executes its strategic shift toward high-margin software and services, driving Owlet360 subscription growth past 120,000 subscribers. Hardware sales remain steady, supported by international expansion of the medically-certified Dream Sock. Gross margins stabilize between 50% and 52%, and Adjusted EBITDA meets the upgraded guidance of $7 million to $9 million for FY 2026.

Bull CaseUpside scenario

Owlet's successful pivot to a high-margin subscription-first model (Owlet360) and the commercial launch of its OnCall telehealth platform will drive predictable, recurring revenue streams. This software-led strategy, combined with regulatory barriers as the only FDA-cleared OTC infant monitor, positions the company to achieve sustainable profitability and expand its market share.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First and only FDA-cleared over-the-counter medical pulse oximetry solution for infants (Dream Sock), establishing a strong regulatory moat.
Rapidly scaling high-margin subscription engine (Owlet360) with over 115,000 paying subscribers as of Q1 2026.
Significant upward revision of FY 2026 Adjusted EBITDA guidance to $7M-$9M (representing 250% to 350% growth over 2025) reflecting strong operational efficiency.
Expansion of the ecosystem into pediatric telehealth with the launch of the Owlet OnCall platform, increasing customer lifetime value (LTV).

Key Investment Risks

High concentration of manufacturing and supply chain exposure to volatile tariff environments, currently impacting margins by 510 bps per quarter.
Demographic headwinds from declining fertility rates in core geographic markets like the United States and the United Kingdom.
History of net losses and ongoing cash burn from operating activities ($5.05 million cash outflow in Q1 2026).
Intense competition from alternative smart baby monitors (e.g., Nanit, Eufy) that do not require wearable sensors.

Thesis Invalidation Triggers

Paying subscribers for Owlet360 decline quarter-over-quarter, indicating a failure in the subscription-based business model transition.
Gross margins drop below 48% due to unmitigated tariff increases or supply chain disruptions.
Failure of the Owlet OnCall Telehealth platform to gain meaningful traction or generate incremental service revenue.
Regulatory actions or product recalls by the FDA or international medical authorities that restrict the sale of the Dream Sock.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.